As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue adjustment affecting Pluvicto. Novartis raised its full-year guidance, projecting double-digit sales ...

Sales rose by nine percent to $12.8 billion, with the gain driven by higher volumes, including a 50 percent jump in sales of Pluvicto prostate cancer treatment thanks to a new production facility ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. But some may not be satisfied with the prostate cancer med’s ...

Revenues from Pluvicto, a prostate cancer drug that is seen as pioneering a class of precision radiotherapies, rose a currency-adjusted 50% to $386 million, but just 36% when stripping out a ...

We achieved important indications expansions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and we completed our PSMAfore filing for Pluvicto in the US. With the momentum in ...

Revenues from Pluvicto, a prostate cancer drug that is seen as pioneering a class of precision radiotherapies, rose a currency-adjusted 50% to $386 million, but just 36% when stripping out a ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Sales rose by nine percent to $12.8 billion, with the gain driven by higher volumes, including a 50 percent jump in sales of Pluvicto prostate cancer treatment thanks to a new production facility ...

NEW YORK – Novartis is gearing up to meet threefold growth in patient demand for Pluvicto (vipivotide tetraxetan), betting ... Novartis' other FDA-approved radiopharmaceutical, Lutathera (lutetium Lu ...